A Phase 2a Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs CS 1103 (Primary)
- Indications Drug toxicity; Substance-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Clear Scientific
- 11 Dec 2024 Status changed from planning to not yet recruiting.
- 11 Sep 2024 New trial record
- 10 Sep 2024 According to a Clear Scientific media release, based on positive results of phase I study the company is working toward an accelerated registration pathway with Phase 2 studies to begin in early 2025.